A Phase I, Open-label, Single-arm Multiple Dose Trial to Investigate Pharmacokinetics and Absolute Bioavailability of BI 1467335 Administered as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [C-14] BI 1467335 After Single and Multiple Oral Doses in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2018
Price : $35 *
At a glance
- Drugs BI 1467335 (Primary) ; BI 1467335 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Diabetic retinopathy; Non-alcoholic steatohepatitis; Renal fibrosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 11 Jun 2018 Status changed from active, no longer recruiting to completed.
- 08 May 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Apr 2018 Status changed from not yet recruiting to recruiting.